Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse. (20th November 2018) - Cohen, Oliver C.; Counsell, Nicholas; Rabin, Neil; Popat, Rakesh; Owen, Roger G.; Popova, Bilyana; Schofield, Oliver; Clifton‐Hadley, Laura; Lyons‐Lewis, Janet; Rawstron, Andy; Spence, Christopher; de Tute, Ruth M.; et al.